Development and validation of an in vitro micronucleus assay platform in TK6 cells
Zhanna Sobol(Pfizer (United States)), Maik Schuler(Pfizer (United States)), Kelley E. Sanok(Pfizer (United States)), Michael L. Homiski(Pfizer (United States)), Dingzhou Li(Pfizer (United States)), Donna Dickinson(Pfizer (United States)), Stephanie L. Coffing(Pfizer (United States)), Richard A. Spellman(Pfizer (United States)), Jennifer B. Munzner(Pfizer (United States)), Jennifer Cheung(Pfizer (United States)), Krista L. Dobo(Pfizer (United States)), Andrew D. Scott(Pfizer (United States)), William C. Gunther(Pfizer (United States))
Mutation Research/Genetic Toxicology and Environmental Mutagenesis
March 13, 2012
Cited by 39
Related Papers
Strategy for genotoxicity testing: Hazard identification and risk assessment in relation to in vitro testing
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2006|131
Advantages and limitations of using fluorescence in situ hybridization for the detection of aneuploidy in interphase human cells
|Mutation Research Letters|1995|119
Improvement of in vivo genotoxicity assessment: Combination of acute tests and integration into standard toxicity testing
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2010|106
Synthesis, Molecular Editing, and Biological Assessment of the Potent Cytotoxin Leiodermatolide
|Journal of the American Chemical Society|2014|93
A critical evaluation of centromeric labeling to distinguish micronuclei induced by chromosomal loss and breakage in vitro
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|1997|89